Normalizing the HIV conversation with your provider

Two stories about HIV came out of the medical press within a day of each other in early August, and they only make sense read together. One says providers need to talk about HIV more. The other says that even where providers are talking about it, the newest prevention tool is not reaching everyone equally.

The push to normalize the conversation

On August 6, 2026, the American College of Obstetricians and Gynecologists issued updated guidance advising providers to normalize conversations about HIV screening and PrEP during routine visits, not just when a patient raises the topic first. The statement recommends offering at least one lifetime HIV test to every patient through an opt-out approach, and it points out that ob-gyns provide close to half of all women’s preventive health visits each year, often the only contact some patients have with the health system at all.

The reasoning behind the push is straightforward. Research consistently shows that one of the biggest factors in whether someone gets tested is whether their doctor brings it up. Waiting for a patient to ask puts the burden on the person least likely to know it is worth asking. Shifting that burden onto routine care, folded into the same shared decision-making providers already use for contraceptive counseling, is meant to make the conversation feel as ordinary as any other preventive topic.

Access is not catching up as fast

The day before the ACOG statement, Medscape reported on new data presented at the AIDS 2026 conference showing that uptake of lenacapavir, the newer long-acting injectable PrEP option, is substantially lower among Black, Hispanic, and younger patients compared with white and older patients. One researcher put it bluntly to the audience: within just six months of release, the same inequities researchers have tracked for 14 years of oral PrEP were already showing up again.

Put the two stories side by side and the picture is clear. Providers are being told, correctly, to bring up prevention more often and treat it as routine. But a system-level push to talk about HIV more does not by itself close the gap in who actually gets access to the newest tools once the conversation happens. Both things can be true and both need attention.

This is also part of why we treat HIV status differently at Protecht. Sharing your HIV status through the app is permanently free, not a promotional feature. It reflects a belief that the ability to disclose accurately, and to have that disclosure trusted, should not depend on what someone can afford or how comfortable their provider is bringing up the subject first.

What this means for you

If your provider has not brought up HIV testing or PrEP recently, ACOG’s own guidance says that is worth raising yourself, at your next routine visit. And if you are curious about newer PrEP options, ask directly rather than assuming your provider will default to whichever one is most convenient to prescribe. The data suggests that default is not landing evenly across patients yet.

Sources

• Normalize Patient Conversations About HIV and PrEP, ACOG Advises, Medscape, August 6, 2026
• Human Immunodeficiency Virus Screening and Preexposure Prophylaxis, ACOG Committee Statement No. 32
• Lenacapavir PrEP Uptake in US Remains Low, Especially Among Black, Hispanic, and Young, Medscape, August 5, 2026